Table 1. Summary of patient... | American Society of Hematology

Table 1.

Summary of patient characteristics and results for cases undergoing therapy with imatinib or rIFNα

Patient no.	Sex	Age at diagnosis, y	Rx	Dose	F/U, mo	Response	% V617F on treatment	% V617F before treatment
1	M	26	Imatinib	800 mg/d	5	NR	44	ND
2	F	60	Imatinib	700 mg/d	5	PR	41	34
3	M	49	Imatinib	800 mg/d	9	NR	89	71
4	F	67	Imatinib	500 mg/d	9	PR	91	88
5	M	58	Imatinib	400 mg/d	10	PR	72	ND
6	M	48	Imatinib	800 mg/d	15	PR	57	40
7	M	31	Imatinib	800 mg/d	17	PR	76	63
8	F	48	Imatinib	500 mg/d	17	CR	8	25
9	F	28	Imatinib	800 mg/d	19	PR	83	82
10	M	72	Imatinib	400 mg/d	21	NR	72	ND
11	M	54	Imatinib	300 mg/d	24	CR	21	44
12	M	43	Imatinib	400 mg/d	25	PR	60	40
13	M	30	Imatinib	600 mg/d	25	PR	19
14	M	53	Imatinib	700 mg/d	31	PR	30	ND
15	F	32	rIFNα	3 MU 3 times/wk	13	CR	19	ND
16	F	39	rIFNα	3 MU 5 days/wk	45	CR	39	ND
17	M	53	rIFNα	3 MU/day	50	CR	29	ND
18	F	48	rIFNα	4 MU, alternate d	60	PR	87	ND
19	M	42	rIFNα	2 MU 3 times/wk	60	CR	27	ND
20	M	52	rIFNα	4.25 MU 3 times/wk	108	CR	22	ND
21	M	39	rIFNα	3.5 MU/d	132	CR	25	ND

Patient no.	Sex	Age at diagnosis, y	Rx	Dose	F/U, mo	Response	% V617F on treatment	% V617F before treatment
1	M	26	Imatinib	800 mg/d	5	NR	44	ND
2	F	60	Imatinib	700 mg/d	5	PR	41	34
3	M	49	Imatinib	800 mg/d	9	NR	89	71
4	F	67	Imatinib	500 mg/d	9	PR	91	88
5	M	58	Imatinib	400 mg/d	10	PR	72	ND
6	M	48	Imatinib	800 mg/d	15	PR	57	40
7	M	31	Imatinib	800 mg/d	17	PR	76	63
8	F	48	Imatinib	500 mg/d	17	CR	8	25
9	F	28	Imatinib	800 mg/d	19	PR	83	82
10	M	72	Imatinib	400 mg/d	21	NR	72	ND
11	M	54	Imatinib	300 mg/d	24	CR	21	44
12	M	43	Imatinib	400 mg/d	25	PR	60	40
13	M	30	Imatinib	600 mg/d	25	PR	19
14	M	53	Imatinib	700 mg/d	31	PR	30	ND
15	F	32	rIFNα	3 MU 3 times/wk	13	CR	19	ND
16	F	39	rIFNα	3 MU 5 days/wk	45	CR	39	ND
17	M	53	rIFNα	3 MU/day	50	CR	29	ND
18	F	48	rIFNα	4 MU, alternate d	60	PR	87	ND
19	M	42	rIFNα	2 MU 3 times/wk	60	CR	27	ND
20	M	52	rIFNα	4.25 MU 3 times/wk	108	CR	22	ND
21	M	39	rIFNα	3.5 MU/d	132	CR	25	ND

Rx indicates treatment; F/U, follow-up (= time of sampling) after starting rIFNα or imatinib; NR, no response; ND, not determined; PR, partial response; CR, complete response; and MU, million units.

View Large

This Feature Is Available To Subscribers Only